Therapeutics: Interleukin-6 (IL-6); IL-6 receptor (CD126); K-Ras (KRAS); signal transducer and activator of transcription 3 (STAT3)

Cancer

INDICATION: Lung cancer

Patient sample, cell culture and mouse studies suggest inhibiting IL-6-CD126 signaling could help treat mutant KRAS-driven lung cancer. In patients with mutant KRAS-driven lung

Read the full 262 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE